Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records

BridgeBio Pharma (BBIO) presented Phase 3 data for Encaleret in autosomal dominant hypocalcemia type 1, showing improved PTH levels and symptoms. The company also began a Phase 3 trial for chronic hypoparathyroidism. The FDA accepted its New Drug Application under Priority Review, with a target action date of May 8, 2027. BBIO shares closed at $65.35, up 0.48%.

BridgeBio Pharma (BBIO) presented data at HFSA 2026 showing acoramidis reduced hospitalization risk in ATTR-CM patients. The study compared 910 acoramidis-treated patients with 1,774 tafamidis-treated patients, finding a 18% lower risk of composite endpoints (p<0.01) and 27% lower cardiovascular hospitalization risk (p<0.001). BBIO stock closed at $65.35, up 0.48%.

BridgeBio Pharma (BBIO) presented data showing acoramidis, its drug for ATTR-CM, had lower clinical event risks compared to tafamidis. The study, using U.S. electronic records, found an 18% lower composite risk (p<0.01). BBIO stock closed at $65.35, up 0.48%, and rose 0.60% in overnight trading.

BridgeBio Pharma (BBIO) reported positive Phase 3 trial results for encaleret, showing significant clinical improvements in treating autosomal dominant hypocalcemia type 1. The company's P/S ratio is 17.81, below its historical median, reflecting market caution. Insiders sold $118.4M in shares, while gurus showed mixed activity. BBIO's GF Score is 67, indicating strong growth but weak profitability and financial strength.

BridgeBio Pharma (BBIO) reported positive Phase 3 trial results for acoramidis, showing reduced hospitalizations and lower diuretic use in ATTR-CM patients. The company's P/S ratio is 17.81, below its historical median of 37.6x, reflecting market caution. Insiders sold $118.4 million in shares over the past year, while gurus showed mixed activity. BBIO has a market cap of $12.78 billion and a GF Score of 67, indicating moderate fundamental quality with strong growth but weak financial health.

BridgeBio Pharma reported an EHR study showing acoramidis reduced event risk by 18% compared to tafamidis in 2,684 ATTR-CM patients. The study also found a 25-27% lower hospitalization risk. The company cited these results as reinforcing acoramidis' differentiation.